Online Makale
Online Hizmetlere Toplu BakışSisli Etfal Tip Bülteni
Med Bull Sisli Etfal Hosp. 1997; 31(3): 10-16 | |||
Metastazı ve Lenfadenopatisi Olan ve Olmayan Kanserli Hastalarda Fosfoheksozizomeraz (PHI) ve Aldolaz (ALO) Serum Düzeylerinin ÖnemiFethi Akgül1, Alparslan Mayadağlı2, Yılmaz Tezcan2, Alper Özkan2, Zerrin Özgen2, Oktay Incekara21ŞişliEtfal Hastanesi Biokimya Kliniği2Şişli Etfal Hastanesi Onkoloji Kliniği AMAÇ: Kanserli hastalarda fosfoheksoz izomeraz (PHI) ve Aldolaz (ALD) serum düzeylerinin araştırılması. Valııe of Serum Phosphohexose Isomerase (PHI) and Aldolase (ALO) Levels in Cancer Patients with Without Metastasis and LymphadenopathyFethi Akgül1, Alparslan Mayadağlı2, Yılmaz Tezcan2, Alper Özkan2, Zerrin Özgen2, Oktay Incekara21ŞişliEtfal Hastanesi Biokimya Kliniği2Şişli Etfal Hastanesi Onkoloji Kliniği PURPOSE: in this study, we invastigated serum levels of phosphohexose isomerase (PHI) and aldolase (ALD) in cancer patients.
MATERIALS AND METHODS: The study included 100 cancer patients with histopathologic diagnosis and 50 healthy control subjects. The patients' ages ranged from 12 to 79 years with an average of 50 years. Of 100 patients 51 were males and 49 were females. The control groups' ages ranged from 16 to 70 years with an average of 42.6 years and %46 years and %46 were males and %54 were females. Analysis of PHI and ALD levels were made by using commercially available kits. Result were evaluated using levene's test. Cancer types included lung cancer (27%), breast cancer (25%), gastrointestinal cancers (15%), genitourinary system cancers (9%), nasopharynx-larynx cancers (6%), sarcoma (6%), lymphoma (3%) and the others (9%). Fethi Akgül, Alparslan Mayadağlı, Yılmaz Tezcan, Alper Özkan, Zerrin Özgen, Oktay Incekara. Valııe of Serum Phosphohexose Isomerase (PHI) and Aldolase (ALO) Levels in Cancer Patients with Without Metastasis and Lymphadenopathy. Med Bull Sisli Etfal Hosp. 1997; 31(3): 10-16 Sorumlu Yazar: Yılmaz Tezcan, Türkiye |
|